
Bioventus (BVS) Stock Forecast & Price Target
Bioventus (BVS) Analyst Ratings
Bulls say
Bioventus Inc. reported a strong quarterly performance, with its surgical solutions segment generating $55.5 million in revenue, reflecting a growth of 10.3% when excluding the impact of divestitures, driven by effective sales execution of the Exogen bone stimulation system. The company's pain treatments business also exhibited robust performance, achieving $79.7 million in revenue and expected to benefit from increased investments targeting growth in various areas including peripheral nerve stimulation and ultrasound technologies. Management projects that both the surgical solutions segment will grow at a low-double-digit percentage in 2026 and significant improvements in adjusted EBITDA margins are anticipated between 2025 and 2030, indicating a positive growth trajectory for the company.
Bears say
Bioventus Inc's financial outlook appears negative due to anticipated elevated investment levels in key growth areas, which may result in stable to declining adjusted EBITDA margins in the upcoming years. The company experienced a substantial decline in restorative therapies revenue by 26.0%, alongside a decrease in international revenue of 8.6%, indicating potential challenges in revenue generation. Additionally, the gross margin fell short of expectations, registering at 68.9% against an estimate of 69.5%, further underscoring underlying financial pressures.
This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares